Table 1.
Munoz-Marmol et al. [10] & Ariza et al. [9]; Pinol-Ripoll et al. [18] | Goldfarb et al. [6] | Arbustini et al. [4] | Cetin et al. [5] | Henderson et al. [11] | McLaughlin et al. [7] | Harada et al. [8] | This study | |
---|---|---|---|---|---|---|---|---|
DES variants (NM_001927.3) | c.[521_541del]; [521_541del] | c.[1078 G > C]; [1178 A > T] | c.[46 C > T]; [46 C > T] | c.[1289-2 A > G]; [1289- 2 A > G] | c.[226delA]; [322 G > T] | c.[600delG]; [1285 C > T] | c.[655 A > C]; [655 A > C] | c.[569 T > C]; [1289-741 G > A] |
p.[(Ala174_Arg180del)]; [(Ala174_Arg180del)] | p.[(Ala360Pro)]; [(Asn393Ile)] | p.[(Arg16Cys)]; [(Arg16Cys)] | p.[(Arg429_Glu430ins16)]; [(Arg429_Glu430ins16)] | p.[(Thr76Profs*22)]; [(Glu108*)] | p. [(Lys201Argfs*20)]; [(Arg429*)] | p.[(Thr219Pro)]; [(Thr219Pro)] | p.[(Leu190Pro)]; [(Thr431Serfs*43)] | |
Age of onset | 15 y; infancy | 2 y, 9 y, 10 y | NR | 15 y, 27 y | Early childhood | Early childhood | 13 y | 25–29 y |
Myopathy | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Generalised weakness, distal atrophy; | Progressive weakness/ wasting | Limb girdle weakness/wasting | Limb girdle weakness/fatigue | Limb girdle weakness | Limb weakness/ wasting | Limb girdle weakness/wasting | ||
Cardiomyopathy | Yes | Yes | Yes | No | No | Yes | Yes | Yes |
Restrictive, Atrioventricular block | Atrioventricular block | Restrictive, Atrioventricular block | Dilated | Hypertrophic | Dilated | |||
Muscle biopsy | ||||||||
Aggregates | Yes | Yes | Yes | No | No | NR | Yes | No |
Myofibrillar disarray | Yes | NR | NR | No | Yes | NR | NR | Yes |
Fibre splitting | Yes | NR | NR | Yes | Yes | NR | NR | Yes |
Dystrophic appearance | Atrophic | NR | NR | Dystrophic | NR | NR | Atrophic | Dystrophic |
Central nuclei | Yes | NR | NR | Yes | Yes | NR | NR | Yes |
NR not reported